Mealey's Drugs & Devices

  • April 22, 2024

    Walgreens To Pay $110 Million To Philadelphia For Role In City’s Opioid Crisis

    PHILADELPHIA — Philadelphia announced April 19 that it has reached a $110 million settlement with Walgreen Co. to settle claims that its failure to monitor suspicious opioid prescriptions or ensure that it dispensed opioid pain medications for a legitimate medical purpose caused harm to the city.

  • April 19, 2024

    Endo Health Pleads Guilty In Michigan Federal Court To Mislabeling Opioid Drug

    DETROIT — Endo Health Solutions Inc. (EHSI) on April 18 pleaded guilty in a Michigan federal court to violating the Food, Drug and Cosmetic Act (FDCA) by marketing its opioid drug Opana ER as crush and tamper resistance.

  • April 18, 2024

    Mass Tort Cases For Drugs, Medical Devices

    New developments in the following mass tort drug and device cases are marked in boldface type.

  • April 18, 2024

    Federal Circuit Defines ‘Surgical Intervention’ In Vaccine Injury Act Appeal

    WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals found that a lower court “relied upon a legally erroneous construction of ‘surgical intervention’” and reversed and remanded a decision that a claim was ineligible for compensation under the National Childhood Vaccine Injury Act.

  • April 17, 2024

    Settlement With Eli Lilly Over Insulin Costs Falls Apart In National Class Action

    NEWARK, N.J. — A proposed settlement between Eli Lilly & Co. and class members in which the drugmaker would pay $13.5 million for an insulin price claims fund and ensure that class members will have prices for certain Lilly insulins capped at $35 a month for four years is off the table, lawyers for the plaintiffs told a New Jersey federal judge.

  • April 17, 2024

    Taxotere MDL Judge Denies Motions For Reconsideration Of Dismissed Cases

    NEW ORLEANS — The Louisiana federal judge overseeing the Taxotere hair loss multidistrict litigation denied 10 motions for reconsideration filed by plaintiffs whose cases were dismissed for failure to comply with a court-ordered deadline to properly serve their complaints.

  • April 17, 2024

    FDA Recalls Heart Devices Linked To Injuries, Death

    SILVER SPRING, Md. — The U.S. Food and Drug Administration has announced a recall of nearly 14,000 HeartMate II and HeartMate 3 Left Ventricular Assist System (LVAS), citing reports that buildup in components can obstruct the device and make it less effective in helping the heart pump blood.

  • April 17, 2024

    Plaintiffs In ASD-ADHD MDL Appeal Judgment, Exclusion Of Experts To 2nd Circuit

    NEW YORK — Plaintiffs in the acetaminophen autism spectrum disorder-attention deficit hyperactivity disorder (ASD-ADHD) multidistrict litigation who allege that prenatal exposure to acetaminophen causes autism or attention deficit hyperactivity disorder have appealed to the Second Circuit U.S. Court of Appeals a decision by the MDL judge to exclude their expert witnesses and to enter final judgment dismissing their cases.

  • April 17, 2024

    Deadlines For 1st Bellwether Trials In Covidien Hernia Mesh MDL Pushed Back

    BOSTON — The federal magistrate judge overseeing the multidistrict litigation involving Covidien hernia mesh agreed to extend dates in the current scheduling order by eight months after the plaintiffs cited “significant discovery deficiencies” on the part of the defendants.

  • April 16, 2024

    High Court Declines Woman’s Request To Review Lactaid Labeling Claim Dismissal

    WASHINGTON, D.C. — The U.S. Supreme Court on April 15 denied woman’s petition to review a First Circuit U.S. Court of Appeals ruling that her claims that she was misled into purchasing Lactaid products are preempted by the U.S. Food and Drug Administration’s statutory enforcement authority under the Food, Drug and Cosmetic Act (FDCA).

  • April 15, 2024

    JPMDL Won’t Transfer Hawaii Drug Pricing Suit To Insulin Pricing MDL

    WASHINGTON, D.C. — The Judicial Panel on Multidistrict Litigation (JPMDL) refused to transfer a case pending in a Hawaii federal court in which the state alleges “a scheme to inflate the list price of all ‘brand-name prescription drugs’ — a substantially larger universe of drugs, manufacturers, and business practices than those at issue in the MDL” that centralized federal insulin pricing lawsuits.

  • April 15, 2024

    JPMDL: OTC Cold Medicine MDL Will Include Maximum Strength Label Cases

    WASHINGTON, D.C. — The Judicial Panel on Multidistrict Litigation (JPMDL) agreed to transfer cases involving “Maximum Strength” labeling on over-the-counter cough and cold medications containing the active ingredient phenylephrine (PE) to the multidistrict litigation for cases alleging that the medications are ineffective at relieving nasal congestion.

  • April 12, 2024

    West Viriginia: Mifepristone Maker Lacks Standing In 4th Circuit Appeal

    RICHMOND, Va. — A West Virginia prosecutor and the state’s attorney general tell the Fourth Circuit U.S. Court of Appeals that it should reject arguments from an abortion drug manufacturer that a state law curtailing the use of the drug violated the U.S. Constitution.

  • April 12, 2024

    Federal Judge Denies Man’s Summary Judgment Motion In Defective Hip Device Case

    FRANKFORT, Ky. — A Kentucky federal judge found that “estoppel should not be applied offensively in the face of inconsistent judgments” and denied a man’s motion for partial summary judgment in a Pinnacle hip implant products liability case.

  • April 12, 2024

    Judge In Exactech MDL Denies Request For In Camera Meeting To Discuss Settlement

    BROOKLYN, N.Y. — The federal judge overseeing the Exactech orthopedic device multidistrict litigation denied a request filed by the device manufacturer for an in camera, off-the-record conference to discuss a potential global settlement.

  • April 12, 2024

    Tepezza Hearing Loss MDL Judge Clarifies Discovery Order, OKs Bellwether Extension

    CHICAGO — The judge overseeing the Tepezza hearing loss multidistrict litigation clarified an order he signed in March compelling Horizon Therapeutics USA Inc. to hand over certain information to reflect that the drug manufacturer disputes the relevance of data that was requested by the plaintiffs.

  • April 11, 2024

    Alabama Federal Judge Grants Motions To Dismiss In 2 Taxotere Cases

    MONTGOMERY, Ala. — An Alabama federal judge in nearly identical orders granted two motions to dismiss filed in a pair of cases that were remanded from the Taxotere hair loss multidistrict litigation after finding that certain claims are time-barred and the rest are inadequately pleaded.

  • April 11, 2024

    Judge Grants Compounding Pharmacy’s Motion To Dismiss Case Filed By Lilly

    MIAMI — A federal judge in Florida said he joins “colleagues around the country” in finding that Eli Lilly & Co.’s claims that a compounding pharmacy violated the Florida Drug and Cosmetic Act (Florida DCA) are preempted by federal law.

  • April 11, 2024

    Publix Asks Opioid MDL Judge To Certify Questions To Georgia Supreme Court

    CLEVELAND — Publix Super Markets Inc. has asked the Ohio federal judge overseeing the opioid multidistrict litigation to certify to the Georgia Supreme Court a series of questions for the high court to determine how the state’s public nuisance law applies in the litigation.

  • April 10, 2024

    Consent Decree Entered; Philips Barred From Making, Selling CPAP Products

    PITTSBURGH — A Pennsylvania federal judge on April 9 entered a consent decree of permanent injunction, prohibiting Philips Respironics from manufacturing or selling continuous positive air pressure (CPAP) sleep apnea devices and respirators in the United States until certain requirements are met.

  • April 10, 2024

    Pharma Companies Seek High Court Review Of Ruling Reversing FCA Suit Dismissal

    WASHINGTON, D.C. — Pharmaceutical companies accused of violating the False Claims Act (FCA) by artificially inflating drug prices filed a petition for writ of certiorari in the U.S. Supreme Court, seeking review of the Ninth Circuit U.S. Court of Appeals’ reversal of a district court’s dismissal of a qui tam suit against them, arguing, in part, that the panel “created a circuit split by holding that a relator can avoid the public disclosure bar by ‘stitching together’ public disclosures.”

  • April 09, 2024

    McKinsey MDL Judge OKs $39.5M Settlement Agreement With Tribal Plaintiffs

    SAN FRANCISCO — The California federal judge presiding over the McKinsey & Co. opioid promotion multidistrict litigation has signed off on a $39.5 million settlement reached between the consulting company and a group of Native American tribes.

  • April 09, 2024

    2nd Circuit Agrees Statute Of Limitations Bars Defective Medical Device Suit

    NEW YORK — The Second Circuit U.S. Court of Appeals agreed that a woman’s product liability and breach of warranty claims against two medical device companies were properly dismissed by a district court and denied the woman’s appeal of the summary judgment award.

  • April 04, 2024

    Mass Tort Cases For Drugs, Medical Devices

    New developments in the following mass tort drug and device cases are marked in boldface type.

  • April 04, 2024

    Oral Arguments Set For Theranos’ Elizabeth Holmes Fraud Conviction Appeal

    SAN FRANCISCO — The Ninth Circuit U.S. Court of Appeals will hear oral arguments on June 11 in Theranos Inc. founder Elizabeth Holmes’ appeal of her conviction; Holmes argues that there was insufficient evidence to convict her of defrauding investors in her blood testing startup and that she was prevented from presenting exculpatory evidence.

Can't find the article you're looking for? Click here to search the Mealey's Drugs & Devices archive.